Palbociclib, potentially marketed as Palbotiz is a cyclin-dependent kinase (CDK) 4/6 inhibitor used primarily for treating hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in adults. The 125 mg dose is the standard starting dose for most patients.

### Key Information on Palbociclib 125 mg (Palbotiz 125):
- *Uses*:
 - Indicated in combination with an aromatase inhibitor (e.g., letrozole) as initial endocrine-based therapy for postmenopausal women or men with HR-positive, HER2-negative advanced or metastatic breast cancer.
 - Also used with fulvestrant in patients with disease progression after prior endocrine therapy.
 - May be combined with inavolisib and fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated breast cancer in patients with progression during or after hormonal treatment.

- *Dosage and Administration*:
 - *Standard Dose*: 125 mg once daily for 21 consecutive days, followed by 7 days off (28-day cycle).
 - Taken orally with food (capsules) or with/without food (tablets). Swallow whole; do not crush, chew, or open.
 - Take at the same time each day. If a dose is missed or vomited, skip it and take the next dose as scheduled—do not double up.
 - Dose adjustments (e.g., to 100 mg or 75 mg) may be required for side effects (e.g., neutropenia) or drug interactions (e.g., with strong CYP3A inhibitors). Always follow your doctor’s guidance.

- *Side Effects*:
 - *Common*: Neutropenia (low white blood cell count), infections, fatigue, nausea, diarrhea, hair loss, vomiting, decreased appetite, rash, anemia, weakness, fever, stomatitis (mouth inflammation).
 - *Serious*: Severe neutropenia, infections, pulmonary embolism, low red blood cell/platelet counts, and rare lung inflammation (symptoms: dry cough, chest pain, shortness of breath). Seek medical attention immediately for serious symptoms.
 - Most side effects are reversible upon dose reduction or discontinuation.

- *Precautions*:
 - *Pregnancy/Breastfeeding*: Can cause fetal harm; use effective contraception during treatment and for at least 3 weeks after (women) or 3 months after (men). Breastfeeding is not recommended during treatment and for 3 weeks after the last dose.
 - *Drug Interactions*: Avoid strong CYP3A inhibitors (e.g., ketoconazole, itraconazole) or inducers (e.g., rifampin, carbamazepine), as they can alter palbociclib levels. Avoid grapefruit products. Inform your doctor of all medications and supplements.
 - *Monitoring*: Regular blood tests (complete blood count) are required, typically at the start of each cycle, on day 15 of the first two cycles, and as needed to monitor for low blood cell counts.

- *Storage*: Store at 68–77°F (20–25°C) in the original container, away from children.
- *Overdose*: No specific antidote. Contact a doctor or poison control (1-800-222-1222) immediately for supportive care.

### Notes on Palbotiz 125:
- The term "Palbotiz 125" likely refers to a specific brand or generic version of palbociclib at the standard 125 mg dose. It aligns with the typical dosing for Ibrance or other palbociclib formulations.
- Available strengths are 75 mg, 100 mg, and 125 mg (capsules or tablets). Confirm the exact brand and formulation with your pharmacist or doctor, as "Palbotiz" may be a regional or generic name.
- Palbociclib is a targeted therapy, not traditional chemotherapy, and works by inhibiting cancer cell growth via CDK4/6 pathways.

### Additional Information:
- Not approved for pediatric use (under 18) due to limited safety/efficacy data.
- Men may consider sperm preservation due to potential fertility risks.
- For more details, consult your healthcare provider, pharmacist, or refer to the manufacturer’s resources.

If you have specific questions about Palbotiz 125 (e.g., side effects, cost, or availability) or need clarification on its use, please provide more details, and I can tailor the response further!